Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510134 | 0.85 | SLC6A2 (0.39) | KDM4EALDH1A1TDP1SLC6A2SLC6A4 | |
| SCHEMBL14700537 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL4386425 | 0.83 | SLC6A2 (0.38) | KDM4EALDH1A1SLC6A2SLC6A4OPRD1 | |
| Iodide SCHEMBL27681363 | 0.82 | KDM4E (0.31) | KDM4E | |
| SCHEMBL2892828 | 0.78 | CYP1A2 (0.36) | KDM4EALDH1A1TDP1SLC6A2SLC6A4 | |
| SCHEMBL13076983 | 0.77 | — | — | |
| SCHEMBL2010031 | 0.77 | — | — | |
| SCHEMBL7717160 | 0.77 | — | — | |
| SCHEMBL7713683 | 0.77 | — | — | |
| SCHEMBL29031903 | 0.77 | SIGMAR1 (0.36) | KDM4EALDH1A1TDP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| CN-101184758-B | Novel compounds | GLAXO GROUP LTD | 2012-05-02 | — | — | CN | disclosed |
| US-20100093765-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-20100093766-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | disclosed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | disclosed |
| CN-101184758-A | Novel compounds | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093766-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KDM4E 2392/4885ALDH1A1 4156/4885TDP1 2552/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | KDM4E 2392/4885ALDH1A1 4156/4885TDP1 2552/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | KDM4E 2392/4885ALDH1A1 4156/4885TDP1 2552/4885 |
| US-20100093765-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KDM4E 2392/4885ALDH1A1 4156/4885TDP1 2552/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KDM4E 2392/4885ALDH1A1 4156/4885TDP1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.